Xiao et al. validated that targeting YTHDF2 with the compound DF-A7, which mediates YTHDF2 degradation, effectively controls tumor growth and enhances antitumor efficacy when combined with anti-PD-1/PD-L1 therapy [105]. The gene discussed is YTHDF2; the disease is neoplasm.